MeSH term
Frequency | Condition_Probility | Animals | 67 | 0.0 |
*Colorectal Neoplasms/diagnosis/metabolism/pathology/therapy | 3 | 4.0 |
Humans | 269 | 0.0 |
Alcohol Drinking | 3 | 2.0 |
Antioxidants/pharmacology | 3 | 1.0 |
Aryldialkylphosphatase/genetics/*metabolism | 5 | 71.0 |
Female | 149 | 0.0 |
Male | 168 | 0.0 |
Polymorphism, Genetic | 44 | 0.0 |
Research Support, Non-U.S. Gov't | 164 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 50 | 0.0 |
Sex Factors | 5 | 0.0 |
Smoking/metabolism | 2 | 3.0 |
Adult | 100 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Genotype | 107 | 1.0 |
Ultracentrifugation | 3 | 1.0 |
Aged | 78 | 0.0 |
Aged, 80 and over | 30 | 0.0 |
Aging/*genetics | 2 | 3.0 |
Alleles | 46 | 0.0 |
Amino Acid Substitution | 15 | 1.0 |
Arginine | 2 | 2.0 |
Aryldialkylphosphatase | 167 | 86.0 |
Esterases/*genetics | 56 | 75.0 |
Gene Frequency | 39 | 0.0 |
Longevity/*genetics | 3 | 8.0 |
Blotting, Western | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Kinetics | 16 | 0.0 |
Lipoproteins, HDL/metabolism | 8 | 7.0 |
Protein Binding | 3 | 0.0 |
Rabbits | 11 | 0.0 |
Age of Onset | 2 | 0.0 |
Apolipoproteins E/*genetics | 2 | 0.0 |
Coronary Arteriosclerosis/*genetics | 2 | 8.0 |
Heterozygote | 9 | 0.0 |
Middle Aged | 131 | 0.0 |
Coronary Disease/enzymology/*epidemiology/genetics | 2 | 100.0 |
Genetic Predisposition to Disease | 18 | 0.0 |
Haplotypes | 10 | 0.0 |
Odds Ratio | 13 | 1.0 |
*Polymorphism, Genetic | 56 | 1.0 |
Risk Factors | 42 | 0.0 |
Arginine/genetics | 5 | 3.0 |
Base Sequence | 23 | 0.0 |
Fluorescence | 2 | 0.0 |
Glutamine/genetics | 5 | 10.0 |
Heat | 3 | 0.0 |
Leucine/genetics | 3 | 5.0 |
Methionine/genetics | 3 | 6.0 |
Molecular Sequence Data | 15 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Brazil/epidemiology | 2 | 2.0 |
Cerebrovascular Accident/epidemiology/*genetics | 2 | 25.0 |
Comorbidity | 2 | 0.0 |
Continental Population Groups/genetics | 2 | 2.0 |
Demography | 2 | 1.0 |
Logistic Models | 14 | 1.0 |
Prevalence | 6 | 0.0 |
Risk Assessment | 12 | 1.0 |
*Pharmacogenetics | 2 | 4.0 |
Polymorphism, Genetic/*genetics | 25 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 25 | 0.0 |
Comparative Study | 45 | 0.0 |
DNA/genetics | 3 | 0.0 |
In Vitro | 5 | 0.0 |
Models, Molecular | 3 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Protein Conformation | 5 | 0.0 |
Child | 5 | 0.0 |
*Genetic Predisposition to Disease | 12 | 1.0 |
Linkage Disequilibrium | 6 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
CHO Cells | 4 | 0.0 |
Cricetulus | 2 | 0.0 |
Hamsters | 5 | 0.0 |
Hela Cells | 3 | 0.0 |
Mutation | 3 | 0.0 |
Disease Progression | 4 | 0.0 |
Esterases/*metabolism | 8 | 66.0 |
Lipoproteins, HDL Cholesterol/blood | 12 | 1.0 |
Lipoproteins, LDL/*metabolism | 5 | 2.0 |
Oxidative Stress | 13 | 3.0 |
Renal Dialysis | 4 | 1.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 6 | 14.0 |
*Genetics, Population | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 20.0 |
Aging/*physiology | 2 | 0.0 |
Esterases/*blood/genetics | 13 | 100.0 |
European Continental Ancestry Group | 4 | 0.0 |
Homozygote | 10 | 0.0 |
Smoking | 9 | 2.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Lipoproteins/metabolism | 2 | 1.0 |
Oxidation-Reduction | 24 | 1.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Lipoproteins, LDL/metabolism | 9 | 4.0 |
Aorta/pathology | 3 | 7.0 |
Japan/epidemiology | 3 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Hydrolysis | 7 | 0.0 |
Adolescent | 8 | 0.0 |
Cholesterol/blood | 12 | 1.0 |
Genetic Markers | 3 | 0.0 |
*Multigene Family | 4 | 0.0 |
Antioxidants/metabolism | 6 | 6.0 |
Phenotype | 20 | 0.0 |
Coronary Disease/*genetics | 5 | 8.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Lipids/blood | 13 | 2.0 |
Lipoproteins/blood | 8 | 2.0 |
Polymorphism, Genetic/*physiology | 3 | 4.0 |
Metabolic Detoxication, Drug/genetics | 3 | 15.0 |
Risk | 5 | 0.0 |
Antioxidants/*metabolism | 3 | 3.0 |
Cells, Cultured | 6 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Lipoproteins, LDL/drug effects/*metabolism | 3 | 50.0 |
Mice | 28 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
*Oxidative Stress | 4 | 1.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Reference Values | 13 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Aryldialkylphosphatase/*blood | 9 | 90.0 |
Lipid Peroxidation | 6 | 5.0 |
Malondialdehyde/blood | 3 | 4.0 |
Gene Expression | 2 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Mice, Knockout | 9 | 0.0 |
Age Factors | 9 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Chromosomes, Human, Pair 7/*genetics | 2 | 1.0 |
DNA Mutational Analysis | 3 | 0.0 |
Esterases/*genetics/metabolism | 3 | 75.0 |
Gene Frequency/genetics | 6 | 1.0 |
Genetic Markers/genetics | 3 | 0.0 |
Genetic Screening | 3 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Apolipoproteins B/blood | 3 | 1.0 |
Lipoproteins, LDL/*blood | 4 | 2.0 |
Lipoproteins, LDL Cholesterol/metabolism | 4 | 11.0 |
*Gene Frequency | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Pregnancy | 5 | 0.0 |
Sampling Studies | 3 | 1.0 |
*Alleles | 3 | 0.0 |
Aryldialkylphosphatase/*genetics | 21 | 84.0 |
Asian Continental Ancestry Group/genetics | 4 | 1.0 |
Case-Control Studies | 23 | 0.0 |
European Continental Ancestry Group/genetics | 6 | 0.0 |
Heterozygote Detection | 3 | 0.0 |
Parkinson Disease/*genetics | 4 | 4.0 |
Chi-Square Distribution | 4 | 0.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Genetics, Population | 2 | 0.0 |
Likelihood Functions | 2 | 1.0 |
Polymerase Chain Reaction | 17 | 0.0 |
*Variation (Genetics) | 7 | 0.0 |
*Arginine | 2 | 7.0 |
*Glutamine | 2 | 16.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Thiobarbituric Acid Reactive Substances/analysis | 2 | 9.0 |
Liver Function Tests | 2 | 1.0 |
Prospective Studies | 7 | 0.0 |
ROC Curve | 2 | 1.0 |
*Amino Acid Substitution | 2 | 2.0 |
*Aryldialkylphosphatase | 4 | 66.0 |
Chromosomes, Human, Pair 7/genetics | 3 | 3.0 |
Codon/genetics | 3 | 0.0 |
Esterases/*genetics/physiology | 2 | 66.0 |
Multigene Family | 3 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
Copper/pharmacology | 4 | 7.0 |
Esterases/genetics/*physiology | 2 | 100.0 |
Mice, Transgenic | 5 | 0.0 |
Oxidation-Reduction/drug effects | 3 | 3.0 |
Tissue Distribution | 3 | 0.0 |
Body Mass Index | 6 | 0.0 |
Statistics | 3 | 0.0 |
Apolipoprotein A-I/metabolism | 4 | 5.0 |
Apolipoprotein A-II/metabolism | 2 | 14.0 |
Transfection | 7 | 0.0 |
Esterases/*blood | 8 | 47.0 |
Lipoproteins, HDL/*blood | 6 | 3.0 |
Tunica Intima/pathology | 2 | 7.0 |
DNA Primers | 11 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Apolipoproteins/blood | 4 | 1.0 |
Chromatography, Gel | 3 | 0.0 |
Lipoproteins, HDL/*metabolism | 8 | 6.0 |
Time Factors | 10 | 0.0 |
Sex Distribution | 3 | 1.0 |
Triglycerides/blood | 8 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Regression Analysis | 11 | 0.0 |
Cross-Over Studies | 3 | 0.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Cloning, Molecular | 4 | 0.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
Phospholipids/metabolism | 2 | 1.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
Esterases/*genetics/*metabolism | 5 | 83.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Paraoxon/metabolism | 5 | 83.0 |
Aryldialkylphosphatase/metabolism | 2 | 100.0 |
Carboxylic Ester Hydrolases/metabolism | 3 | 15.0 |
Finland/epidemiology | 5 | 4.0 |
Amino Acid Substitution/genetics | 4 | 1.0 |
Lipid Peroxidation/genetics | 2 | 25.0 |
Dietary Supplements | 2 | 2.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Lipid Peroxidation/drug effects | 4 | 7.0 |
Rats | 9 | 0.0 |
Rats, Wistar | 4 | 0.0 |
Gene Frequency/*genetics | 3 | 2.0 |
Infant, Newborn | 6 | 0.0 |
Coronary Disease/blood/*genetics | 2 | 10.0 |
Promoter Regions (Genetics)/*genetics | 5 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Esterases/blood/genetics/*metabolism | 3 | 100.0 |
Glucose Tolerance Test | 2 | 0.0 |
Homeostasis | 2 | 0.0 |
*Insulin Resistance | 2 | 1.0 |
Lipoproteins, HDL/blood | 2 | 0.0 |
Age Distribution | 2 | 0.0 |
Analysis of Variance | 9 | 0.0 |
Cohort Studies | 10 | 0.0 |
Incidence | 3 | 0.0 |
Esterases/blood/*genetics/metabolism | 3 | 100.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Linkage Disequilibrium/genetics | 3 | 1.0 |
Phenylacetates/metabolism | 3 | 75.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
English Abstract | 8 | 0.0 |
Esterases/*blood/chemistry/genetics | 2 | 100.0 |
Substrate Specificity | 9 | 0.0 |
Phospholipases A/metabolism | 4 | 6.0 |
Proteolipids/metabolism | 2 | 8.0 |
Arteriosclerosis/*metabolism | 3 | 4.0 |
Cell Line | 4 | 0.0 |
Diet, Atherogenic | 3 | 9.0 |
Gene Expression Regulation | 5 | 0.0 |
Exons | 3 | 0.0 |
Species Specificity | 4 | 0.0 |
Environmental Exposure | 2 | 1.0 |
Veterans | 2 | 25.0 |
Linkage (Genetics) | 2 | 0.0 |
Lipids/*blood | 4 | 0.0 |
Apolipoproteins B/metabolism | 2 | 2.0 |
Aryldialkylphosphatase/*metabolism | 6 | 100.0 |
Biological Markers/blood | 4 | 0.0 |
Lipid Peroxidation/*physiology | 2 | 11.0 |
Lipoproteins, HDL Cholesterol/metabolism | 3 | 6.0 |
Turkey/epidemiology | 2 | 2.0 |
Esterases/blood/*genetics | 9 | 64.0 |
Diabetes Mellitus, Type 2/blood/*enzymology | 2 | 33.0 |
Reproducibility of Results | 3 | 0.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
DNA/blood | 2 | 1.0 |
Esterases/biosynthesis/*genetics | 2 | 100.0 |
Brain/drug effects/enzymology | 2 | 16.0 |
Catalysis | 2 | 0.0 |
Diaphragm/drug effects/enzymology | 2 | 100.0 |
Insecticides/metabolism | 3 | 60.0 |
Metabolic Detoxication, Drug | 5 | 6.0 |
Autopsy | 2 | 1.0 |
Coronary Vessels/enzymology/pathology | 2 | 50.0 |
Genetic Predisposition to Disease/etiology/genetics | 2 | 66.0 |
Amino Acid Sequence | 10 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
China/ethnology | 2 | 1.0 |
Child, Preschool | 3 | 0.0 |
Infant | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Organophosphorus Compounds/metabolism | 2 | 22.0 |
Predictive Value of Tests | 2 | 0.0 |
Lactones/*metabolism | 3 | 50.0 |
Esterases/genetics/metabolism | 3 | 75.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Platelet Activating Factor/metabolism | 2 | 12.0 |
Esterases/genetics/*metabolism | 6 | 100.0 |
Lipoproteins/*metabolism | 2 | 1.0 |
Cholesterol/*blood | 2 | 0.0 |
Indians, North American/*genetics | 2 | 2.0 |
Lipoproteins, HDL Cholesterol/*blood | 3 | 1.0 |
Lipoproteins, LDL Cholesterol/*blood | 2 | 2.0 |
*Lipid Peroxidation | 3 | 6.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 3 | 8.0 |
Esterases/blood/*genetics/*metabolism | 2 | 100.0 |
Leucine/*genetics | 2 | 8.0 |
Methionine/*genetics | 2 | 13.0 |
Austria/epidemiology | 2 | 14.0 |
Turkey | 5 | 3.0 |
DNA/*analysis | 2 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Esterases/*blood/*genetics | 4 | 100.0 |
Lipid Peroxidation/*genetics | 2 | 50.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Coronary Disease/epidemiology/*genetics | 3 | 23.0 |
Smoking/*adverse effects | 2 | 0.0 |
Carboxylic Ester Hydrolases/blood | 5 | 55.0 |
Aryldialkylphosphatase/*genetics/*metabolism | 2 | 100.0 |
Multivariate Analysis | 7 | 0.0 |
Insecticides/*toxicity | 3 | 15.0 |
*Organophosphorus Compounds | 5 | 16.0 |
Esterases/*blood/deficiency/genetics | 2 | 100.0 |
Liver/metabolism | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Aryldialkylphosphatase/blood/*genetics | 7 | 100.0 |
China/epidemiology | 2 | 1.0 |
Probability | 2 | 0.0 |
Lipoproteins, LDL/blood | 3 | 1.0 |
Persian Gulf Syndrome/*enzymology | 2 | 100.0 |
Arteriosclerosis/*enzymology | 3 | 25.0 |
Cholesterol/metabolism | 2 | 0.0 |
India | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Ultrasonography, Doppler | 2 | 7.0 |
Arginine/*genetics | 4 | 7.0 |
Glutamine/*genetics | 3 | 17.0 |
Coronary Disease/genetics | 2 | 5.0 |
China | 3 | 0.0 |
Disease Susceptibility | 3 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Cattle | 3 | 0.0 |
Chickens | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Bromosuccinimide/pharmacology | 2 | 66.0 |
Dicyclohexylcarbodiimide/pharmacology | 2 | 50.0 |
Diethyl Pyrocarbonate/pharmacology | 2 | 22.0 |
Butyrylcholinesterase/blood | 2 | 33.0 |
Oxidants/pharmacology | 4 | 6.0 |
Indicators and Reagents | 2 | 0.0 |
Microsomes, Liver/*enzymology | 2 | 1.0 |
Osmolar Concentration | 2 | 0.0 |
Cardiovascular Diseases/*physiopathology | 2 | 18.0 |
Taiwan | 2 | 1.0 |
Aryldialkylphosphatase/*physiology | 4 | 100.0 |
Lipids/metabolism | 3 | 0.0 |
Aryldialkylphosphatase/blood | 4 | 66.0 |
Italy | 2 | 0.0 |
Arteriosclerosis/physiopathology | 2 | 9.0 |
Diet | 3 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Insulin/blood | 3 | 0.0 |
Lipoproteins/*blood | 2 | 0.0 |
Leucine | 2 | 4.0 |
Methionine | 2 | 5.0 |
Models, Biological | 2 | 0.0 |
Turkeys | 2 | 12.0 |
Continental Population Groups/*genetics | 2 | 4.0 |
Treatment Outcome | 2 | 0.0 |
Coronary Angiography | 3 | 1.0 |
Codon | 3 | 0.0 |
Coronary Disease/enzymology/epidemiology/*genetics | 2 | 40.0 |
Genetic Heterogeneity | 2 | 0.0 |
Blood Pressure | 2 | 0.0 |
Apolipoproteins C/*genetics | 2 | 2.0 |
Apolipoproteins E/genetics | 3 | 0.0 |
Esterases/genetics | 3 | 16.0 |
Apolipoprotein A-I/blood | 2 | 1.0 |
Hypochlorous Acid/*pharmacology | 2 | 18.0 |
*Chromosome Mapping | 2 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Organophosphorus Compounds | 2 | 16.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Alzheimer Disease/*genetics | 2 | 0.0 |
Diastole | 2 | 2.0 |
Sex Characteristics | 2 | 0.0 |
Systole | 2 | 2.0 |
Isoenzymes/blood/genetics | 2 | 11.0 |
Liver/enzymology | 2 | 0.0 |
*Renal Dialysis | 4 | 0.0 |
Aryldialkylphosphatase/*blood/*genetics | 2 | 100.0 |
Japan | 3 | 0.0 |
Confidence Intervals | 3 | 0.0 |
Aryldialkylphosphatase/*blood/genetics | 2 | 100.0 |
Oxidative Stress/physiology | 5 | 7.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Aryldialkylphosphatase/*genetics/*pharmacology | 2 | 100.0 |
Spectrophotometry | 2 | 1.0 |
Cross-Sectional Studies | 3 | 0.0 |
Environment | 2 | 2.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Agriculture | 2 | 20.0 |
*Occupational Exposure | 2 | 1.0 |
Lipoproteins, LDL Cholesterol/drug effects/metabolism | 2 | 100.0 |
Thyroid Function Tests | 2 | 2.0 |
Cholinesterases/metabolism | 2 | 18.0 |
Cytochrome P-450 CYP2E1/genetics | 2 | 5.0 |
Glutathione Transferase/genetics | 3 | 1.0 |
Insecticides/*poisoning | 2 | 20.0 |
Syndrome | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
